Background: Post-mortem studies with brain samples of schizophrenic patients led revealed altered GABA-ergic markers like reduced expression of the GABA transporter GAT-1. Whether this effect is due to the pathophysiology of schizophrenia or to antipsychotic treatment has not been investigated. We therefore established an animal trial of long-term antipsychotic treatment to address this question.
Methods: A total of 33 adult male rats were investigated in three cohorts of 11 animals. One group received clozapine (45 mg/kg/day), another group haloperidol (1.5 mg/kg/day), and the third one pH-adapted water over a period of 6 months. In situ hybridization with cRNA probes specific for GABA transporters VGAT, GAT-1 and GAT-3 were performed in comparison to control animals.
Results: While GAT-1 was upregulated, VGAT expression declined in cortical and limbic brain regions, whereby haloperidol showed a greater effect than clozapine. GAT-3 expression was suppressed in parietal and temporal cortex.
Conclusions: We thus conclude that long-term antipsychotic treatment alters GABA transporter expression in rat. The upregulation of GAT-1 contrasts with the post-mortem finding of reduced GAT-1 expression in schizophrenic patients. Our results facilitate the distinction between disease dependent changes of GABAergic markers and medication effects.
References
-
1
Adler G, Grieshaber S, Faude V, Thebaldi B, Dressing H.
Clozapine in patients with chronic schizophrenia: Serum level, EEG and memory performance.
Pharmacopsychiatry.
2002;
35
190-194
-
2
Akbarian S, Kim J J, Potkin S G, Hagman J O, Tafazzoli A, Bunney W E Jr,. et al .
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.
Arch Gen Psychiatry.
1995;
52
258-266
Dr. med. Mathias Zink
Central Institute of Mental Health
P.O. Box 12 21 20
68072 Mannheim
Germany
Phone: +49 621 1703 125
Fax: +49 621 23429
Email: zink@kv.zi-mannheim.de
